A Novel Intergenic Region (chr2: 30,316,870)- ALK Fusion in a Patient with Lung Adenocarcinoma Responding to Crizotinib Combined with Pemetrexed Treatment: A Case Report.
Danfei ZhouJun YingShanshan HuJiangdong LiHaijian Liu
Published in: OncoTargets and therapy (2024)
fusion by using targeted NGS, and highlight the efficacy of crizotinib combined with pemetrexed to reduce unbearable gastrointestinal adverse reactions. It provides valuable clinical guidance for the treatment of similar cases in the future.